A subsequent study on mammary carcinoma imputed to Kruppel-like factor 2 (KLF2) the shifting of ATRA signaling from the pro-oncogenic FABP5/PPARβ/δ path to the anti-carcinogenic CRABPII/RAR pathway, inducing the expression of CRABPII and inhibiting the expression of FABP5 and PPARβ/δ [77]. The gene discussed is FABP5; the disease is breast carcinoma.